Navigation Links
U.S. District Court Rules in Favor of Lilly in Amylin Litigation
Date:6/8/2011

INDIANAPOLIS, June 8, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. District Court for the Southern District of California ruled in Lilly's favor, vacating a temporary restraining order and denying a request by Amylin Pharmaceuticals for a preliminary injunction that sought to impose restrictions on the Lilly Diabetes sales force and other relief. Amylin recently filed litigation involving the two companies' diabetes collaboration agreement.

"We are pleased with the Court's decision to vacate the temporary restraining order and deny Amylin's request for a preliminary injunction," said Robert A. Armitage, senior vice president and general counsel for Lilly "We have complied with our contractual obligations under our agreements with Amylin, and done so in a manner fully consistent with all applicable laws. We believe that Amylin's allegations against Lilly are entirely without merit and we fully expect to prevail in this litigation."

Enrique Conterno, president of Lilly Diabetes, said, "We are committed to offering a broad range of treatment options, including important new therapies, to people with diabetes and their health care providers. There is more work to be done, and we will continue to work hand in hand with all of our diabetes partners to achieve better outcomes for patients."

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs.  Additional information about Lilly is available at www.lilly.com.  C-LLY

This press release contains forward-looking statements about our alliance with Amylin, and it reflects Lilly's current beliefs. There are substantial risks and uncertainties in the process of drug development and commercialization. Further, we cannot predict the outcome of any litigation with Amylin or its effect on our collaboration. For further discussion of risks and uncertainties, please see Lilly's latest Forms 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO)


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amylin Pharmaceuticals Issues Statement Regarding U.S. District Court Order
2. U.S. District Court Order Maintains Patent Exclusivity for Lillys Cymbalta
3. Watson Confirms District Court Ruling in Generic Fentora® Patent Suit
4. Watson Announces Favorable District Court Ruling in Generic Fentora® Patent Suit
5. Watson Announces Favorable District Court Ruling in Generic Mucinex® Patent Suit
6. Sensipar® Patents Upheld By District Court
7. Winner Medical Honored with Shenzhen Baoan District Quality Award
8. U.S. District Court Rules from Bench in Lillys Favor, Confirms Validity of Alimta Patent
9. German District Court Finds RENASYS™ GO NPWT System Non-infringing
10. Capital District Health Authority and IWK Health Centre to Implement Anesthesia Information Management System
11. Renhuang Wins Bid to Supply All-Natural Products to Guangzhou Military District
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... May 4, 2017  DarioHealth Corp. (NASDAQ: DRIO), a ... big data solutions, today announced that it is teaming ... STI Technologies Limited to lower diabetes healthcare costs in ... innoviCares card, which is available throughout all provinces and ... will be eligible for additional savings when shopping for ...
(Date:5/3/2017)... 2017 A Catheterization Laboratory is an ... facility. Commonly referred to as cath lab, this ... imaging technology to give physicians visual access to ... spaces, a team of physicians perform life-saving procedures ... intervention, congenital heart defect closure, stenotic heart valves, ...
(Date:5/3/2017)... Pa. , May 3, 2017  West ... in innovative solutions for injectable drug administration, announced ... Scientific Affairs and Technical Services, and Diane ... workshops and offering presentations focused on West,s expertise ... injectable products, as well as providing commentary on ...
Breaking Medicine Technology:
(Date:5/26/2017)... MN (PRWEB) , ... May 26, 2017 , ... A ... U.S. states with the healthiest seniors are located in the Midwest. With the average ... more and more people are concerned with both the quality and affordability of where ...
(Date:5/26/2017)... , ... May 26, 2017 , ... After raising nearly ... Top gadget will continue to be available at a discounted crowdfunding price on ... stress wherever they are, I also wanted to bring a fidget toy to the ...
(Date:5/26/2017)... ... May 26, 2017 , ... Dr. Alex Rabinovich, a highly-skilled oral surgeon specializing ... blog post on insurance options. If a Bay Area patient has to search for ... and money. Visiting an in-network provider for a second opinion can ensure a patient ...
(Date:5/26/2017)... , ... May 26, 2017 , ... “Just What Happened in the Garden of Eden”: ... the Garden of Eden” is the creation of published author, Penelope Colt, mother, trader, horse ... family moved to NYC when she was three. At six, they moved to Dayton, ...
(Date:5/24/2017)... ... May 24, 2017 , ... In modern research, success ... appropriate instruments for research and understanding the basic principles that were designed to ... on innovations in stereo microscopy for brightfield and fluorescence typically used in laboratories ...
Breaking Medicine News(10 mins):